Poolbeg Pharma PLC (POLB.L)
Chart Events
Performance Outlook
| Previous Close | 4.6500 |
| Open | 4.6000 |
| Bid | 4.5000 x N/A |
| Ask | 4.9000 x N/A |
| Day's Range | 4.5000 - 4.9000 |
| 52 Week Range | 4.1340 - 13.3000 |
| Volume | |
| Avg. Volume | 1,592,067 |
| Market Cap | 23.5M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.00 |
- ACCESSWIRE
Poolbeg Pharma PLC Announces Appointment of Joint Broker
July 29, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) ('Poolbeg' or the 'Company'), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has appointed Singer Capital Markets as Joint Broker with immediate effect. finnCap Ltd will continue to act as Nominated Adviser and Joint Broker alongside J&E Davy as additional Joint Broker.
- ACCESSWIRE
Poolbeg Pharma PLC Announces POLB001 Human Challenge Clinical Trial To Commence
Poolbeg Pharma (Poolbeg Pharma plc) (AIM:POLB)(OTCQB:POLBF), ('Poolbeg' or the 'Company'), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has received ethics and competent authority approval to commence its Lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a strain agnostic, small molecule immunomodulator which aims to address the unmet medical need for a treatment for severe
- Simply Wall St.
Here's Why We're Not At All Concerned With Poolbeg Pharma's (LON:POLB) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
